Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 15, 2012. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure and share buyback activity.
- Shares Purchased: 705,000 Ordinary shares of 25 pence each.
- Purchase Date: February 15, 2012.
- Price Range: Highest price paid was 1,424.5 pence per share; lowest price paid was 1,410.5 pence per share.
- Treasury Holdings (Settled): 502,582,927 shares (9.05% of total issued share capital).
- Treasury Holdings (Including Unsettled): 503,772,927 shares (9.97% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,050,885,179 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 705,000 shares on the open market. This transaction increased the percentage of total voting rights held in Treasury from the prior level to 9.97% when including unsettled shares.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules regarding share buybacks.
Investor Verification Checklist
- Verify the total number of shares in issue (5,050,885,179) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the current percentage of voting rights held in Treasury (9.97% including unsettled shares).
- Review the price paid per share (1,410.5 to 1,424.5 pence) against market prices on February 15, 2012.
- Note that this filing does not contain financial performance data; refer to the most recent Form 20-F or interim results for revenue and profit metrics.